PABPC1L induces IDO1 to promote tryptophan metabolism and immune suppression in renal cell carcinoma

类型：

作者：Shu Guannan, Chen Minyu, Liao Wuyuan, Fu Liangmin, Lin Mingjie, Gui Chengpeng, Cen Junjie, Lu Jun, Chen Zhenhua, Wei Jinhuan, Chen Wei, Wang Yinghan, Zhu Jiangquan, Zhao Tianxin, Liu Xiaonan, Jing Jiajia, Liu Guo-Chang, Pan Yihui, Luo Junhang, Zhang Jiaxing
期刊：CANCER RESEARCH
阅读原文

The tumor microenvironment (TME) in renal cell carcinomas (RCC) is marked by substantial immunosuppression and immune resistance despite having extensive T-cell infiltration. Elucidation of the mechanisms underlying immune evasion could help identify therapeutic strategies to boost the efficacy of immune checkpoint blockade (ICB) in RCC. This study uncovered a mechanism wherein the polyadenylate-binding protein PABPC1L modulates indoleamine 2,3-dioxygenase 1 (IDO1), a prospective target for immunotherapy. PABPC1L was markedly upregulated in RCC, and high PABPC1L expression correlated with unfavorable prognosis and resistance to ICB. PABPC1L bolstered tryptophan metabolism by upregulating IDO1, inducing T-cell dysfunction and Treg infiltration. PABPC1L enhanced the stability of JAK2 mRNA, leading to increased JAK2-STAT1 signaling that induced IDO1 expression. Additionally, PABPC1L-induced activation of the JAK2-STAT1 axis created a positive feedback loop to promote PABPC1L transcription. Conversely, loss of PABPC1L diminished IDO1 expression, mitigated cytotoxic T-cell suppression, and enhanced responsiveness to anti-PD-1 therapy in patient-derived xenograft models. These findings reveal the crucial role of PABPC1L in facilitating immune evasion in RCC and indicate that inhibiting PABPC1L could be a potential immunotherapeutic approach in combination with ICB to improve patient outcomes.